Ganguly, Anirban
Tyagi, Shachi
Chermansky, Christopher
Kanai, Anthony
Beckel, Jonathan
Hashimoto, Mamoru
Cho, Kang Jun
Chancellor, Michael
Kaufman, Jonathan
Yoshimura, Naoki
Tyagi, Pradeep http://orcid.org/0000-0001-6586-4545
Funding for this research was provided by:
National Institute of Health (R44DK108397, CA251341, CA263243)
Article History
Accepted: 26 January 2023
First Online: 6 March 2023
Declarations
:
: This work was partly supported by National Institutes of Health Grants: R44DK108397, CA251341, and CA263243.
: Michael Chancellor and Jonathan Kaufman are board members of Lipella Pharmaceuticals. Pradeep Tyagi is a consultant for Vensica Therapeutics and Uropharma.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: AG and ST wrote the initial draft and performed the literature search; CC, AK, and JB offered valuable suggestions to modify the draft; MC, JK, and NY edited and help secure funding; PT was responsible for the overall theme, direction, and formatting of the submitted work.